<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733431</url>
  </required_header>
  <id_info>
    <org_study_id>TR-VENUS</org_study_id>
    <nct_id>NCT03733431</nct_id>
  </id_info>
  <brief_title>Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study</brief_title>
  <acronym>TR-VENUS</acronym>
  <official_title>Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkish Stroke Research and Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turkish Neurological Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ElectroCore INC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turkish Stroke Research and Clinical Trials Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine safety and feasibility of non-invasive transcutaneous cervical
      Vagus nerve stimulation (nVNS) when delivered promptly after clinical diagnosis of acute
      stroke. Vagus nerve stimulation will be performed via GammaCore® device. A total of 60
      patients will be randomized to each of 3 different groups; 'standard dose' vagal stimulation,
      'high dose' vagal stimulation, and 'sham stimulation' (1:1:1 ratio). Adverse device events,
      serious adverse device events, and feasibility of vagal nerve stimulation at the setting of
      acute stroke will be evaluated. The study will be performed in a multi-center fashion among
      stroke centers within TurkStrokeNet Network.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular effects, clinical worsening or death (primary safety measure)</measure>
    <time_frame>24 hours</time_frame>
    <description>any of the following:
severe bradycardia (HR ≤50/min) during treatment application
significant decrease in arterial blood pressure (≥20 mmHg decrease in mean arterial blood pressure) during treatment application
neurological worsening (progression of neurologic deficit as shown by ≥ 4 points increase in NIH Stroke Scale Score) within 24 hours
death within 24 hours</description>
  </primary_outcome>
  <other_outcome>
    <measure>Proportion of treatment eligible patients (feasibility measure 1)</measure>
    <time_frame>6 hours</time_frame>
    <description>Proportion of eligible patients in whom nVNS can be started within the first 6 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients completing all pre-specified treatment doses (feasibility measure 2)</measure>
    <time_frame>12 hours</time_frame>
    <description>Proportion of enrolled patients who receive all the pre-specified treatment doses per protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke onset to treatment time (feasibility measure 3)</measure>
    <time_frame>6 hours</time_frame>
    <description>Time from stroke onset to administration of the first dose of nVNS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Early neurological outcome (efficacy measure 1)</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients with NIHSS score≤4 or improvement of baseline NIHSS score ≥8 at 24 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Early tissue outcome (efficacy measure 2)</measure>
    <time_frame>24 hours</time_frame>
    <description>Delta infarct volume between baseline DWI and 24 hr MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Local reaction at application site (secondary safety measure 1)</measure>
    <time_frame>12 hours</time_frame>
    <description>Local irritation or skin reaction during treatment application</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute coronary syndrome (secondary safety measure 2)</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute coronary syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic intracerebral hemorrhage (secondary safety measure 3)</measure>
    <time_frame>24 hours</time_frame>
    <description>Symptomatic intracerebral hemorrhage: ≥ 4 points increase in NIH Stroke Scale Score (NIHSS) together with a PH2 (parenchymal hematoma-2) type intracerebral hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Death, clinical worsening, and acute coronary syndrome (secondary safety measure 4)</measure>
    <time_frame>24 hours</time_frame>
    <description>Combined outcome of death, clinical worsening, and acute coronary syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>New ischemic lesion or increase in hemorrhage (secondary safety measure 5)</measure>
    <time_frame>24 hours</time_frame>
    <description>New, spatially distinct remote ischemic lesion outside the arterial territory of the index lesion on MRI at 24 hours or greater than 30% increase in hemorrhage volume from baseline CT to 24 hour MRI in the subset with intracerebral hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse device event (SADE) rate (secondary safety measure 6)</measure>
    <time_frame>24 hours</time_frame>
    <description>Serious adverse device event (SADE) rate at 24 hours</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke</condition>
  <condition>Stroke, Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>Standard dose vagal stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose vagal stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gammacore device</intervention_name>
    <description>Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.</description>
    <arm_group_label>High dose vagal stimulation</arm_group_label>
    <arm_group_label>Standard dose vagal stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gammacore sham device</intervention_name>
    <description>Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.</description>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients who are older than 18 years old who have been admitted to
             neurological intensive care or stroke units with ischemic or hemorrhagic stroke

          -  Patients with symptom onset time within 6 hours or with unknown time of onset and no
             evidence of acute ischemia on fluid attenuation inversion recovery (FLAIR) imaging

          -  Patients who have given written informed consent prior to undertaking any
             study-related procedure.

        Exclusion Criteria:

          -  Patients who have a pre-stroke disability ≥ 2 according to the modified Rankin Score

          -  Patients who have a NIH Stroke Scale/Score (NIHSS) ≤ 4 or ≥30

          -  Patients who have a NIHSS item 1a ≥2

          -  Patients who have experienced early dramatic neurological improvement (NIHSS score
             improvement ≥8) prior to study randomization suggesting resolution of signs/symptoms
             of stroke

          -  Patients with classical lacunar syndrome

          -  Patients who have local infection, rash or space occupying lesion at the stimulation
             site

          -  Patients with a prior injury to the vagus nerve (cervical vagotomy)

          -  Patients with conditions that make the positioning of the device not possible such as
             tonic head deviation or involuntary movements of the head and neck

          -  Patients using medications that can interfere with central neurotransmitter mechanisms
             potentially involved in the central vagal pathway (complete list is provided below
             under concomitant medications)

          -  Patients with known severe (&gt;90% stenosis) bilateral carotid artery disease

          -  Patients with known carotid hypersensitivity

          -  Patients who had undergone bilateral carotid endarterectomy or neck surgery involving
             the region of carotid triangle

          -  Patients who have low blood pressure (Baseline SBP≤100 mmHg or DBP≤60 mmHg)

          -  Patients who have slow heart rate (Baseline HR≤60/min)

          -  Patients who have high blood pressure (SBP&gt;220 mmHg or DBP&gt;130 mmHg) despite initial
             line of treatment

          -  Patients who have been involved in any investigational study within the previous 90
             days

          -  Patients who have any terminal illness such that the patient would not be expected to
             survive more than 90 days

          -  Pregnant women

          -  Patients with severe hypoglycemia at admission (&lt;60 mg/dl)

          -  Patient experiencing seizures

          -  Patients with baseline ECG showing first-degree AV block; second- or third-degree
             atrio-ventricular block with no pacemaker/ICD in place; or ventricular
             tachycardia/fibrillation

          -  Patients with digitalis toxicity

          -  Patients who are suspected to have an acute coronary syndrome after clinical
             evaluations (Clinical, ECG, or any related biomarker)

          -  Patients who are scheduled to have an emergent carotid artery angioplasty stenting or
             endarterectomy

          -  Patients implanted with an electrical and/or neurostimulator device, including but not
             limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain
             stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.

          -  Patients implanted with metal cervical spine hardware or having a metallic implant
             near the GammaCore stimulation site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ethem M Arsava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet A Topcuoglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakan Ay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital, Harvard University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ethem M Arsava, MD</last_name>
    <phone>00905323355172</phone>
    <email>arsavaem@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehmet A Topcuoglu, MD</last_name>
    <phone>00905365753634</phone>
    <email>matopcuoglu@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Canan Togay Işıkay</last_name>
      <phone>00903125956000</phone>
      <email>ctogay@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Canan Togay Işıkay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University Faculty Of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bijen Nazlıel</last_name>
      <phone>0090312202444</phone>
      <email>bijennazliel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bijen Nazlıel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethem M Arsava, MD</last_name>
      <phone>00905323355172</phone>
      <email>arsavaem@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mehmet A Topcuoglu, MD</last_name>
      <phone>005365753634</phone>
      <email>matopcuoglu@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ethem M Arsava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehmet A Topcuoglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akdeniz University</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babur Dora, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskişehir Osmangazi Faculty of Medicine</name>
      <address>
        <city>Eskişehir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atilla Özcam</last_name>
      <phone>00902222393750</phone>
      <email>aozcanozd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Atilla Özcan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan University</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan Huseyin Kozak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Selcuk University</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serefnur Ozturk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayıs University Faculty of Medicine</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Levent Güngör</last_name>
      <phone>00903623121919</phone>
      <email>ligungor@omu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Levent Güngör</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 3, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Ethem Murat Arsava</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>vagal nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

